Evidence map›Paper›PMID 31695504›Full record

ArticleClinical epidemiology2019

Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study.

Michael Tøstesen, Mette Nørgaard, Jan Maxwell Nørgaard, Bruno C Medeiros, Claus Werenberg Marcher, Ulrik Malthe Overgaard, Marianne Tang Severinsen, Claudia Schoellkopf, Lene Sofie Granfeldt Østgård

Abstract read
In one paragraph

Article in Clinical epidemiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michael TøstesenDepartment of Clinical Medicine, Holstebro Regional Hospital, Aarhus, Denmark.
Mette NørgaardDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Jan Maxwell NørgaardDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Bruno C MedeirosDepartment of Hematology, Stanford University, School of Medicine, Stanford, CA, USA.
Claus Werenberg MarcherDepartment of Hematology, Odense University Hospital, Odense, Denmark.
Ulrik Malthe OvergaardDepartment of Hematology, University Hospital Rigshospitalet, Copenhagen, Denmark.
Marianne Tang SeverinsenDepartment of Hematology, Aalborg University Hospital, Aalborg, Denmark.
Claudia SchoellkopfDepartment of Hematology, Herlev University Hospital, Herlev, Denmark.
Lene Sofie Granfeldt ØstgårdDepartment of Clinical Medicine, Holstebro Regional Hospital, Aarhus, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment of acute myeloid leukemia (AML) is widely centralized. Longer distances to a specialized treatment center may affect patients' access to curative-intended treatment. Especially during outpatient treatment, distance may also affect survival. METHODS AND PATIENTS: The authors conducted a national population-based cohort study including all AML patients diagnosed in Denmark between 2000 and 2014. We investigated effects of distance (<10 kilometers [km; reference], 10-25, 25-50, 50-100, >100) to the nearest specialized treatment facility on the probability of receiving intensive chemotherapy, HSCT, and achieving a complete remission (CR) using logistic regression analysis (odds ratios; ORs). For overall survival, we used Cox proportional hazards regression (hazard ratios [HRs]) and adjusted (a) for relevant baseline characteristics.

resultsOf 2,992 patients (median age=68.5 years), 53% received intensive chemotherapy and 12% received low-dose chemotherapy outpatient regimens. The median distance to a specialized treatment center was 40 km (interquartile range=10-77 km). No impact of distance to specialized treatment centers was seen on the probability of receiving intensive chemotherapy (10-25 km, aOR=1.1 (CI=0.7-1.7), 25-50 km, aOR=1.1 (CI=0.7-1.7), 50-100 km, aOR=1.3 (CI=0.9-1.9), and >100 km, aOR=1.4 [CI=0.9-2.2]). Overall survival in patients regardless of therapy (<10 km, aOR=1.0 vs >100 km, aOR=1.0 [CI=0.9-1.2]), in intensive therapy patients, or in patients' choice of post-remission was not affected by distance to specialized treatment center. Distance to a transplant center also did not affect the probability of HSCT or survival post-HSCT.

conclusionIn Denmark, distance to a specialized treatment facility offering remission-induction chemotherapy and HSCT does not negatively affect access to curative-indented therapy, treatment-response, or survival in AML patients.

Indexed as

allogeneic transplantationepidemiologyhematologyprognosissocioeconomics

Identifiers

PMID31695504
PMCPMC6718163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.